Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
Authors:
- György JermendyGJGyörgy Jermendy
- the Hungarian RECAP GroupTGthe Hungarian RECAP Group
- Rajesh BalkrishnanRBRajesh Balkrishnan
Open Access
- 31 October 2008
- journal article
- research article
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 1-8
Abstract
Aim: The objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory Hungarian patients with type 2 diabetes mellitus (T2DM) who were prescribed either a sulfonylurea (SU) or a thiazolidinedione (TZD) in addition to the prior metformin (MF) monotherapy. Methods: Type 2 diabetics aged ≥ 30 years and who had added an SU or TZD to previous MF monotherapy at least 1 year prior to the visit date were identified during January 2006 to March 2007. Information on HbA1c (A1C), medication use and co-morbid conditions was extracted from the medical record up to 6 months prior to the addition of SU or TZD to MF (baseline), and a minimum of one year after the initiation of either SU or TZD. Glycemic control (A1C < 6.5%) was assessed using the last available A1C value in the medical record. Self-reported hypoglycemia, health-related quality of life (HRQoL) and treatment satisfaction were also assessed. Results: A total of 414 patients (82% SU+MF and 18% TZD+MF) with a mean age of 60.5 years (SD = 9.4 years) participated in the study. About 27% of patients reported hypoglycemic episodes, with about one-third reporting episodes that resulted into interruption of activities or required medical/non-medical assistance. Three quarters of patients were not at glycemic goal and BMI was the only factor significantly associated with failure to have an A1C level < 6.5%. Patients' HRQoL was significantly associated with self-reported hypoglycemic episodes (p = 0.017), and duration of diabetes (p = 0.045). Conclusion: Nearly 75% of patients were not at A1C goal of < 6.5% despite using two oral anti-hyperglycemic medications. Approximately 9% of patients reporting hypoglycemia required some kind of medical/non-medical assistance. Greater BMI at baseline was associated with an A1C level ≥ 6.5%. Finally, self- reports of hypoglycemia and duration of diabetes were associated with low HRQoL.Keywords
This publication has 23 references indexed in Scilit:
- Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2006
- Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapyDiabetologia, 2006
- Overcoming the hurdles to achieving glycemic controlMetabolism, 2006
- Utilization of oral antihyperglycemic drugs over a 7–year period (1998–2004) in a Hungarian population and adherence to drug therapyEuropean Journal of Clinical Pharmacology, 2005
- The Burden of Mortality Attributable to DiabetesDiabetes Care, 2005
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2005
- Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth and Quality of Life Outcomes, 2004
- Hypoglycemia as a barrier to glycemic controlJournal of Diabetes and its Complications, 2004
- Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetesThe American Journal of Medicine, 2002
- Health-related Quality of Life in Type 2 Diabetes (T2ARDIS-2)Value in Health, 2000